The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings, Inc. (NTHI) said it is scheduled to meet in person with the FDA on November 17, 2026, for an End-of-Phase 1 Type B meeting about NEO212. NeOnc plans to seek feedback on the clinical program, including the proposed patient population, trial design, endpoints, dose selection, evidence for a future marketing application, and whether a proposed trial design could support a potential accelerated approval pathway. The meeting's scheduling does not establish FDA agreement on a trial design or regulatory pathway.
NeOnc says it completed Phase 1 dose escalation. Dose escalation was discontinued following a dose-limiting toxicity at 810 mg once daily on Days 1 through 5 of a 28-day cycle; 610 mg was selected as the recommended Phase 2 dose. The company reports FDA authorization in September 2025 to proceed with the Phase 2a and Phase 2b portions of the study. It also describes individual Phase 1 outcomes: about 60% tumor reduction and disease control lasting 21 treatment months in one patient with recurrent glioblastoma, and stable disease lasting about 16 months in a patient with lung cancer metastatic to the brain. The company cautions that these outcomes do not establish efficacy and require confirmation in larger studies.
NEONC TECHNOLOGIES HOLDINGS, INC. (symbol: NTHI) is the issuer of record for a Form 8-K filing submitted to the SEC.
GARNETT KEITHLY reported acquisition or exercise transactions in a Form 4 filing for NTHI. The filing lists transactions totaling 5,000 shares at a weighted average price of $3.36 per share on September 15, 2026. Following the reported transactions, holdings were 237,357 shares.
NeOnc Technologies Holdings, Inc. (NTHI) reported that Executive Chairman, President and CEO Amir F. Heshmatpour bought an additional 35,000 shares of common stock in the open market on September 15, 2026, for approximately $115,400 at a weighted average price of about $3.30 per share.
Since the company announced positive topline Phase 2a results for intranasal NEO100 on August 12, 2026, Mr. Heshmatpour has accumulated 111,000 shares for roughly $418,700, while Founder and Chief Medical Officer Thomas C. Chen has purchased 49,016 shares for about $210,000, for combined open‑market purchases of 160,016 shares totaling approximately $629,000.
The Phase 2a NEO100-01 study met its primary endpoint, with six‑month progression‑free survival of 48.9% versus a 20% benchmark (p = 0.0047) and median overall survival of 26.09 months, and follows a previously announced $15 million registered direct offering, while NeOnc’s second program, NEO212, has completed Phase 1 dose escalation and set a recommended Phase 2 dose.
NEONC TECHNOLOGIES HOLDINGS, INC. (symbol: NTHI) is the issuer of record for a Form 4 filing submitted to the SEC. Heshmatpour Amir F reported reported purchase transactions in this Form 4 filing.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported that CEO, President, director and ten percent owner Amir F. Heshmatpour in open-market or private transactions on September 14–15, 2026. The filing also lists substantial through HCWG LLC, KIG LLC and AFH Holdings & Advisory, LLC with various beneficial ownership disclaimers.
No Rule 10b5-1 trading plan is reported for these transactions.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) CEO and director Thomas C. Chen reported open-market purchases of a total of 10,798 shares of common stock on September 11 and 14, 2026, through an IRA at prices of $3.60 and $3.815 per share. The filing also reports updated direct and indirect holdings across family-related entities and trusts, with several positions subject to beneficial ownership disclaimers limited to Chen’s pecuniary interests.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported that its chief financial officer, Garnett Keithly, purchased 257 shares of common stock on September 14, 2026 in an open-market transaction at a weighted average price of $3.8948 per share, with trade prices ranging from $3.87 to $3.92. Following this purchase, he holds 242,357 shares of common stock directly, a figure that includes shares held by certain immediate family members for which he disclaims beneficial ownership except to the extent of any pecuniary interest. He is also reported as the beneficial owner of 44,053 shares held indirectly through HCWG LLC by virtue of being the sole member of The Hilkiah Group LLC, which owns a 4.3% interest in HCWG. No Rule 10b5-1 trading plan is reported for these transactions.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) received a Rule 144 notice indicating that officer Keithly Garnett may sell 5,000 shares of common stock through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $18,900, with 25,936,365 shares outstanding as of September 15, 2026.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported that CEO, President and director Amir F. Heshmatpour purchased 37,000 shares of common stock on September 11, 2026 at a weighted average price of $3.6654 per share in open-market or private transactions. Following this purchase, he holds 3,133,000 shares directly, which the filing states includes 275,000 shares held by certain immediate family members for which he disclaims beneficial ownership except to the extent of his pecuniary interest. He also reports indirect holdings of 256,120 shares through HCWG LLC representing only his proportionate interest, 550,000 shares through KIG LLC, where his spouse is the sole member and for which he similarly disclaims beneficial ownership except for any pecuniary interest, and 3,714,020 shares through AFH Holding & Advisory, LLC, where he is the sole member and manager. The filing indicates these transactions were not reported under a Rule 10b5-1 trading plan.
NeOnc Technologies Holdings, Inc. (NTHI) entered into securities purchase agreements for a registered direct offering of 3,571,430 shares of common stock (or pre-funded warrants in lieu) and accompanying warrants to purchase up to 3,571,430 shares at a combined purchase price of $4.20 per share (or $4.1999 per pre-funded warrant) and warrant. Gross proceeds are estimated at $15 million before a 7.0% placement fee and expenses. Warrants are immediately exercisable at $4.20 per share and expire five years from issuance; pre-funded warrants have a $0.0001 exercise price and remain exercisable until fully exercised, both subject to beneficial ownership limitations.
The transaction is a takedown from NeOnc’s effective Form S-3 shelf registration. The company plans to use net proceeds for working capital and general corporate purposes and to redeem Series A Convertible Preferred Stock. Closing is expected on or about September 10, 2026, subject to customary conditions. NeOnc agreed to a 30-day restriction on new equity issuances, while the Chief Executive Officer and Chief Medical Officer entered into 90-day lock-up agreements.